UBS Group
OLMA icon

UBS Group’s Olema Pharmaceuticals OLMA Stock Holding History

UBS Group’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Sell
222,873
-162,188
-42% -$2.17M ﹤0.01% 4780
2026
Q1 		$5.74M Buy
385,061
+91,501
+31% +$2.04M ﹤0.01% 3926
2025
Q4 		$7.34M Sell
293,560
-897,094
-75% -$16M ﹤0.01% 3627
2025
Q3 		$11.7M Sell
1,190,654
-221,445
-16% -$1.33M ﹤0.01% 3124
2025
Q2 		$6.02M Buy
1,412,099
+260,952
+23% +$1.16M ﹤0.01% 3682
2025
Q1 		$4.33M Buy
1,151,147
+590,641
+105% +$2.97M ﹤0.01% 3931
2024
Q4 		$3.27M Buy
560,506
+482,959
+623% +$4.82M ﹤0.01% 4241
2024
Q3 		$926K Sell
77,547
-81,078
-51% -$1.04M ﹤0.01% 4721
2024
Q2 		$1.72M Sell
158,625
-14,536
-8% -$158K ﹤0.01% 3921
2024
Q1 		$1.96M Buy
173,161
+120,663
+230% +$1.56M ﹤0.01% 3983
2023
Q4 		$737K Buy
52,498
+38,495
+275% +$517K ﹤0.01% 4762
2023
Q3 		$173K Buy
14,003
+12,493
+827% +$127K ﹤0.01% 5457
2023
Q2 		$13.6K Buy
1,510
+1,154
+324% +$6.97K ﹤0.01% 7036
2023
Q1 		$1.24K Sell
356
-3,732
-91% -$15.2K ﹤0.01% 8775
2022
Q4 		$10K Buy
4,088
+1,657
+68% +$4.83K ﹤0.01% 8584
2022
Q3 		$7K Buy
+2,431
New +$10.3K ﹤0.01% 8891
2022
Q2 		– Sell
-26
Closed – – 10738
2022
Q1 		$0 Sell
26
-104
-80% -$573 ﹤0.01% 10707
2021
Q4 		$1K Buy
+130
New +$2.69K ﹤0.01% 10008
2021
Q2 		– Sell
-636
Closed -$21K – 9679
2021
Q1 		$21K Sell
636
-52,617
-99% -$2.25M ﹤0.01% 7340
2020
Q4 		$2.56M Buy
+53,253
New +$2.5M ﹤0.01% 3153

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

UBS Group's OLMA Position: Q2 2026 in Review

UBS Group reduced its Olema Pharmaceuticals (OLMA) stake by 42% in Q2 2026, selling an estimated $2.17M and leaving 222,873 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #4780.

UBS Group first reported a position in OLMA in Q4 2020 and has held it in 20 quarters since. The position peaked at $11.7M in Q3 2025. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • UBS Group held 222,873 shares of Olema Pharmaceuticals worth $2.79M as of Q2 2026.
  • UBS Group sold 162,188 Olema Pharmaceuticals shares in Q2 2026, an estimated $2.17M.
  • Olema Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4780 holding.
  • UBS Group first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • UBS Group's Olema Pharmaceuticals position peaked at $11.7M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.